MedTrace Logo

Analysis of Diphenylcyclopropenone (DPCP) in Normals

NCT01452594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-09-05

No results posted yet for this study

Summary

The drug diphenylcyclopropenone, or DPCP, modifies the immune system and has been shown to be effective in treating certain kinds of cancer. This study hopes to improve our understanding of how this drug helps create an effective immune response.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Diphenylcyclopropenone

Topical administration

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • James Krueger, MD,PhD · Rockefeller University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01452594 on ClinicalTrials.gov